(May 2015) In April, the Gates Center for Regenerative Medicine celebrated the grand opening of the Gates Biomanufacturing Facility, which will serve academic, clinical and commercial investigators looking to translate their laboratory discoveries into clinical-grade protein and cell-based products suitable for investigational use in humans.
The Gates Biomanufacturing Facility will be the only site within a 500-mile radius that complies with the U.S. Food and Drug Administration’s manufacturing regulations, creating a significant resource to researchers on the Anschutz Medical Campus.
The facility is an important investment in our faculty by a partnership that includes the Gates Center, the Anschutz Medical Campus, the School of Medicine, University of Colorado Health, Children’s Hospital Colorado and the Gates Frontier Fund. Diane Gates Wallach, a board member of the Gates Frontier Fund, described the fund’s support as “venture philanthropy,” a commitment of resources that seeks to spur significant growth in our community.
“Some of our young faculty who literally have developed new techniques for cell expansion—that no one else in the world has been able to do—would be lost to other